TP53 and breast cancer: In TP53-mutated (T47D and MDA-MB231) and/or ER-negative (MDA-MD231) breast cancer cells, we detected no significant differences in cells treated with SASP, however in MCF7 cells, which are TP53 WT and ER-positive, we observed marks of cellular senescence.